STEPHEN JOHN KISH

Summary

Affiliation: Centre for Addiction and Mental Health
Country: Canada

Publications

  1. ncbi request reprint Striatal dopaminergic and serotonergic markers in human heroin users
    S J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Neuropsychopharmacology 24:561-7. 2001
  2. ncbi request reprint Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease
    Stephen J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada
    Brain 131:120-31. 2008
  3. pmc Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study
    Stephen J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario M5T 1R8, Canada
    Brain 133:1779-97. 2010
  4. pmc Pharmacologic mechanisms of crystal meth
    Stephen J Kish
    Department of Psychiatry and Pharmacology, University of Toronto, Toronto, Ont
    CMAJ 178:1679-82. 2008
  5. ncbi request reprint Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region?
    Stephen J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada M5T 1R8
    Nucl Med Biol 32:123-8. 2005
  6. doi request reprint Low striatal serotonin transporter protein in a human polydrug MDMA (ecstasy) user: a case study
    S J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada
    J Psychopharmacol 24:281-4. 2010
  7. ncbi request reprint How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy?
    Stephen J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, M5T 1R8, Toronto, Ontario, Canada
    Pharmacol Biochem Behav 71:845-55. 2002
  8. ncbi request reprint Elevated activity of phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson's disease
    B M Ross
    Centre for Addiction and Mental Health, University of Toronto, Ontario, Toronto, Canada
    Neuroscience 102:899-904. 2001
  9. ncbi request reprint Dopamine D1-stimulated adenylyl cyclase activity in cerebral cortex of autopsied human brain
    J Tong
    Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health Clarke Division, 250 College Street, Toronto, Ontario, M5T 1R8, Canada
    Neurochem Int 39:117-25. 2001
  10. ncbi request reprint Serum prolactin in symptomatic and asymptomatic dopa-responsive dystonia due to a GCH1 mutation
    Y Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division, Toronto, Ontario, Canada
    Neurology 61:269-70. 2003

Research Grants

Collaborators

Detail Information

Publications49

  1. ncbi request reprint Striatal dopaminergic and serotonergic markers in human heroin users
    S J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Neuropsychopharmacology 24:561-7. 2001
    ..Our data suggest that chronic heroin exposure might produce a modest reduction in dopaminergic and serotonergic activity that could affect motivational state and impulse control, respectively...
  2. ncbi request reprint Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease
    Stephen J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada
    Brain 131:120-31. 2008
    ....
  3. pmc Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study
    Stephen J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario M5T 1R8, Canada
    Brain 133:1779-97. 2010
    ....
  4. pmc Pharmacologic mechanisms of crystal meth
    Stephen J Kish
    Department of Psychiatry and Pharmacology, University of Toronto, Toronto, Ont
    CMAJ 178:1679-82. 2008
    ..There is no medication approved for the treatment of relapses of methamphetamine addiction; however, potential therapeutic agents targeted to dopamine and nondopamine (e.g., opioid) systems are in clinical testing...
  5. ncbi request reprint Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region?
    Stephen J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada M5T 1R8
    Nucl Med Biol 32:123-8. 2005
    ..However, there has been no consistency in the selection of a "SERT-free" reference region for the estimation of free and nonspecific binding, as occipital cortex, cerebellum and white matter have all been employed...
  6. doi request reprint Low striatal serotonin transporter protein in a human polydrug MDMA (ecstasy) user: a case study
    S J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada
    J Psychopharmacol 24:281-4. 2010
    ....
  7. ncbi request reprint How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy?
    Stephen J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, M5T 1R8, Toronto, Ontario, Canada
    Pharmacol Biochem Behav 71:845-55. 2002
    ..Until these issues are resolved, it cannot be assumed that ecstasy exposure represents a chronic serotonin deficiency condition...
  8. ncbi request reprint Elevated activity of phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson's disease
    B M Ross
    Centre for Addiction and Mental Health, University of Toronto, Ontario, Toronto, Canada
    Neuroscience 102:899-904. 2001
    ..We suggest that pharmacotherapies which augment this compensatory response might have utility as a treatment for Parkinson's disease...
  9. ncbi request reprint Dopamine D1-stimulated adenylyl cyclase activity in cerebral cortex of autopsied human brain
    J Tong
    Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health Clarke Division, 250 College Street, Toronto, Ontario, M5T 1R8, Canada
    Neurochem Int 39:117-25. 2001
    ..We conclude that dopamine stimulated AC can be measured in cerebral cortex of human brain allowing for the possibility that this process can be examined in human brain disorders in which dopaminergic abnormalities are suspected...
  10. ncbi request reprint Serum prolactin in symptomatic and asymptomatic dopa-responsive dystonia due to a GCH1 mutation
    Y Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division, Toronto, Ontario, Canada
    Neurology 61:269-70. 2003
  11. ncbi request reprint Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations
    Y Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Neurology 56:260-3. 2001
    ..The data expand the clinical spectrum of TH deficiency and suggest that TH mutations may account for some patients with DRD simulating spastic paraplegia...
  12. ncbi request reprint Striatal dopamine in early-onset primary torsion dystonia with the DYT1 mutation
    Y Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health, The Clarke Division, Toronto, Ontario, Canada
    Neurology 54:1193-5. 2000
    ..Our data suggest that the DYT1 mutation is not associated with significant damage to the nigrostriatal DA system, in keeping with the absence of parkinsonism and levodopa response in this disorder...
  13. ncbi request reprint Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding
    Z B Pristupa
    Department of Psychiatry, University of Toronto, Ontario
    Mol Pharmacol 45:125-35. 1994
    ..g., phosphorylation/accessory binding protein) or caused by the existence of multiple molecular forms of the DA transporter is currently unknown...
  14. ncbi request reprint Phospholipid biosynthetic enzymes in human brain
    B M Ross
    Department of Psychiatry, University of Toronto, Ontario, Canada
    Lipids 32:351-8. 1997
    ..In conclusion our data indicate different regulatory properties of PE and PC synthesis in human brain, and suggest that the rate of PE synthesis may be more dependent upon substrate (ethanolamine) availability than that of PC synthesis...
  15. ncbi request reprint Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase I gene mutations
    Y Furukawa
    Human Neurochemical Pathology Laboratory, Clarke Institute of Psychiatry, Toronto, Ontario, Canada
    Ann Neurol 44:10-6. 1998
    ..Our data demonstrate a new phenotype of GCH deficiency associated with compound heterozygosity for GCH gene mutations and suggest the usefulness of combined BH4 and levodopa therapy for this disorder...
  16. ncbi request reprint Brain serotonin transporter binding in non-depressed patients with Parkinson's disease
    M Guttman
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada
    Eur J Neurol 14:523-8. 2007
    ..Further investigation will be required to establish whether SERT binding is more or less decreased in those patients with PD who also have major depressive disorder...
  17. ncbi request reprint Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia
    B M Ross
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada
    Brain Res 821:407-13. 1999
    ....
  18. ncbi request reprint Brain choline acetyltransferase activity in chronic, human users of cocaine, methamphetamine, and heroin
    S J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Mol Psychiatry 4:26-32. 1999
    ..Studies of cognitive and brain cholinergic status in high dose users of MA are warranted...
  19. ncbi request reprint Brain protein and alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease
    F Mastrogiacoma
    Human Neurochemical Pathology Laboratory, Clarke Institute of Psychiatry, Toronto, Canada
    Ann Neurol 39:592-8. 1996
    ..Nevertheless, reduced levels of this rate-limiting enzyme of the Krebs cycle could contribute to the brain neurodegenerative mechanisms of AD...
  20. ncbi request reprint Quinolinic acid catabolism is increased in cerebellum of patients with dominantly inherited olivopontocerebellar atrophy
    S J Kish
    Clarke Institute of Psychiatry, Toronto, Ontario, Canada
    Ann Neurol 29:100-4. 1991
    ..Increased quinolinic acid phosphoribosyltransferase activity may represent a mechanism, in the degenerating cerebellum, to protect quinolinic acid-sensitive granule cells in patients with olivopontocerebellar atrophy...
  21. ncbi request reprint Elevated stimulatory and reduced inhibitory G protein alpha subunits in cerebellar cortex of patients with dominantly inherited olivopontocerebellar atrophy
    S J Kish
    Human Neurochemical Pathology Lab, Clarke Institute of Psychiatry, Toronto, Ontario, Canada
    J Neurochem 60:1816-20. 1993
    ....
  22. ncbi request reprint Brain thiamine, its phosphate esters, and its metabolizing enzymes in Alzheimer's disease
    F Mastrogiacoma
    Human Neurochemical Pathology Laboratory, Clarke Institute of Psychiatry, Toronto, Canada
    Ann Neurol 39:585-91. 1996
    ....
  23. ncbi request reprint Brain glyceraldehyde-3-phosphate dehydrogenase activity in human trinucleotide repeat disorders
    S J Kish
    Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health, Toronto, Ontario, Canada
    Arch Neurol 55:1299-304. 1998
    ....
  24. ncbi request reprint Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations
    Yoshiaki Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division, Toronto, Ontario, Canada
    Mov Disord 19:1256-8. 2004
    ..Our finding suggests a beneficial effect of amantadine on this type of dyskinesia frequently observed in relatively severe dopamine-deficient metabolic disorders...
  25. ncbi request reprint Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine
    Paul S Fitzmaurice
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario M5T 1R8, Canada
    J Pharmacol Exp Ther 319:703-9. 2006
    ..This provides evidence for involvement of oxygen-based free radicals in the action of MA in both dopamine-rich (caudate) and -poor (cerebral cortex) areas of human brain...
  26. ncbi request reprint Inverse relationship between brain noradrenaline level and dopamine loss in Parkinson disease: a possible neuroprotective role for noradrenaline
    Junchao Tong
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Arch Neurol 63:1724-8. 2006
    ..Experimental findings using animal models of Parkinson disease (PD) suggest that noradrenaline might protect dopamine neurons from damage...
  27. ncbi request reprint Marked dissociation between high noradrenaline versus low noradrenaline transporter levels in human nucleus accumbens
    Junchao Tong
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    J Neurochem 102:1691-702. 2007
    ..This suggests that noradrenaline signalling is much less spatially and temporally restricted in the caudomedial accumbens than in other noradrenaline-rich brain areas...
  28. pmc Brain levels of neuropeptides in human chronic methamphetamine users
    Paul S Frankel
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    Neuropharmacology 53:447-54. 2007
    ....
  29. pmc Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users
    Paul S Frankel
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA
    Neuropharmacology 55:41-6. 2008
    ..Our postmortem brain data suggest involvement of striatal dynorphin systems in human cocaine users and should add to the interest in the testing of new dynorphin-related therapeutics for the treatment of cocaine addiction...
  30. doi request reprint Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?
    Isabelle Boileau
    Human Neurochemical Pathology Laboratory, University of Toronto, Toronto, Ontario, Canada
    J Neurosci 28:9850-6. 2008
    ..If correct, (+)[(11)C]DTBZ might be a useful imaging probe to correlate changes in brain dopamine stores and behavior in users of methamphetamine...
  31. ncbi request reprint Identification of a noradrenaline-rich subdivision of the human nucleus accumbens
    Junchao Tong
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    J Neurochem 96:349-54. 2006
    ..The presence of very high, localized noradrenaline concentrations in the caudomedial nucleus accumbens implies a special biological role for this neurotransmitter in human brain motivational processes...
  32. ncbi request reprint Brain antioxidant systems in human methamphetamine users
    Anna Mirecki
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    J Neurochem 89:1396-408. 2004
    ..Increased CuZnSOD and uric acid might reflect compensatory responses to oxidative stress. Future studies are necessary to establish whether these changes are associated with oxidative brain damage in human methamphetamine users...
  33. ncbi request reprint Brain vesicular acetylcholine transporter in human users of drugs of abuse
    Deborah Siegal
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada
    Synapse 52:223-32. 2004
    ..This possibility should be taken into account when utilizing VAChT as a neuroimaging outcome marker for cholinergic neuron number in human studies...
  34. ncbi request reprint Decreased activity of brain phospholipid metabolic enzymes in human users of cocaine and methamphetamine
    Brian M Ross
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ont, Canada M5T 1R8
    Drug Alcohol Depend 67:73-9. 2002
    ..Decreased striatal Ca-PLA(2) and/or PCCT activity in cocaine users might also help to explain why CDP choline, which enhances phospholipid synthesis, reduces craving in some users of the drug cocaine...
  35. ncbi request reprint Brain biopterin and tyrosine hydroxylase in asymptomatic dopa-responsive dystonia
    Yoshiaki Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division, Toronto, Ontario, Canada
    Ann Neurol 51:637-41. 2002
    ..Our data suggest that the extent of striatal tyrosine hydroxylase protein loss may be critical in determining dopa-responsive dystonia symptomatology...
  36. ncbi request reprint Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease?
    Stephen J Kish
    Human Neurochemical Pathology Section, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Adv Neurol 91:39-49. 2003
  37. ncbi request reprint Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users
    Junchao Tong
    Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health, 250 College Street, Toronto, Ontario M5T 1R8, Canada
    Am J Psychiatry 160:896-903. 2003
    ..To establish whether dopamine D(1) receptor function might be altered in human methamphetamine users, the authors measured dopamine-stimulated adenylyl cyclase activity in the brain of chronic human users of the drug...
  38. ncbi request reprint Brain proteasomal function in sporadic Parkinson's disease and related disorders
    Yoshiaki Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    Ann Neurol 51:779-82. 2002
    ..Our brain data suggest that a systemic, global disturbance in the catalytic activity and degradation ability of the proteasome itself is unlikely to explain the cause of Parkinson's disease...
  39. ncbi request reprint Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease
    Paul S Fitzmaurice
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Mov Disord 18:969-76. 2003
    ....
  40. ncbi request reprint Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum
    John W Haycock
    Department of Biochemistry and Molecular Biology, Louisiana State University Health Science Center, New Orleans 70119, USA
    J Neurochem 87:574-85. 2003
    ..This suggests that declines in DA-related function during adulthood and senescence may be explained by losses in DA per se as opposed to DAergic neuropil...
  41. ncbi request reprint What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?
    Stephen J Kish
    Mov Disord 18:1219-23. 2003
  42. ncbi request reprint Dopa-responsive dystonia due to mild tyrosine hydroxylase deficiency
    Yoshiaki Furukawa
    Ann Neurol 55:147-8. 2004
  43. ncbi request reprint Why is parkinsonism not a feature of human methamphetamine users?
    Anna Moszczynska
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario M5T 1R8, Canada
    Brain 127:363-70. 2004
    ..g. levodopa) during drug rehabilitation might be helpful...
  44. ncbi request reprint Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy
    Junchao Tong
    Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health, Toronto, Canada
    Ann Neurol 55:125-9. 2004
    ..The supersensitive dopamine D(1) receptors in both striatum and cerebral cortex in PD might compensate for dopamine deficiency, but could also contribute to long-term complications of levodopa therapy...
  45. ncbi request reprint Use of MDA (the "love drug") and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA)
    Kathryn S Kalasinsky
    Division of Forensic Toxicology, Office of the Armed Forces Medical Examiner, Washington, D C, USA
    J Forensic Sci 49:1106-12. 2004
    ..Drug users and investigators examining possible brain neurotoxic effects of MDMA need to consider that "ecstasy" tablets can contain MDA and methamphetamine despite no demand for the drugs...
  46. pmc Current concepts in the diagnosis and management of Parkinson's disease
    Mark Guttman
    Department of Medicine, University of Toronto, Ont, Canada
    CMAJ 168:293-301. 2003
    ..Surgical treatment is an option for a defined patient population...
  47. ncbi request reprint Altered CTX-catalyzed and endogenous [32P]ADP-ribosylation of stimulatory G protein alphas isoforms in postmortem bipolar affective disorder temporal cortex
    Stavroula Andreopoulos
    Laboratory of Cellular and Molecular Pathophysiology, Center for Addiction and Mental Health, Clarke Site, Toronto, Canada
    J Neurosci Res 72:638-45. 2003
    ..Taken together, these observations suggest that elevations of alpha(s) in BD brain are more likely related to factors affecting the disposition or availability of alpha(s) to this posttranslational enzymatic modification...
  48. ncbi request reprint Does hyperthyroidism increase risk of death due to the ingestion of ecstasy?
    Teri L Martin
    Toxicology Section, Centre of Forensic Sciences, 25 Grosvenor Street, Toronto, ON, Canada M7A 2G8
    J Forensic Sci 52:951-3. 2007
    ....
  49. ncbi request reprint Effects of MDMA (ecstasy) use and abstention on serotonin neurons
    Stephen J Kish
    Lancet 359:1616; author reply 1617-8. 2002

Research Grants4

  1. BRAIN SEROTONIN TRANSPORTER IN ECSTASY AND MDA USERS
    Stephen Kish; Fiscal Year: 2007
    ..More broadly, our data will help define the contribution of different neuroanatomical components of the brain serotonin system to human behavior. ..
  2. PET IMAGING STUDY OF BRAIN VMAT2 IN HUMAN METHAMPHETAMINE USERS
    STEPHEN JOHN KISH; Fiscal Year: 2010
    ..Results might also help in assessing the validity of a brain imaging tool that has been proposed for use in testing whether new neuroprotective drugs slow down the progression of Parkinson's disease. ..